



NEOGEN
CHEMICALS LTD.

May 18, 2020

BSE Limited Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code No: 542665	National Stock Exchange of India Limited Listing Department, Exchange Plaza, BandraKurla Complex, Bandra (East), Mumbai – 400 051 Company Symbol: NEOGEN
--	--

Sub: Intimation of Board Meeting to consider and approve Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2020.

Dear Sir/Madam,

Pursuant to regulation 29 and 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Saturday, May 23, 2020 at 3.00 p.m. through video conferencing due to COVID- 19 pandemic, inter-alia, to consider, approve and take on record the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended on March 31, 2020 and to consider recommendation of a final dividend, if any, on the equity shares of the Company, for the financial year ended March 31, 2020 subject to declaration of the same by the shareholders at the ensuing Annual General Meeting.

Further, as we have informed vide our letter dated March 31, 2020, the trading window closure period has commenced from April 1, 2020 and will end 48 hours after the declaration of Audited Financial Results of the Company for the quarter and financial year ended on March 31, 2020 pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015.

This information is also being uploaded on the Company's Website at www.neogenchem.com

The same may please be taken on record.

Thanking you.

Yours faithfully

For Neogen Chemicals Limited

***Sd/-**

Unnati Kanani
Company Secretary & Compliance Officer
Membership No: ACS 35131
PAN No.- BNBPK0150Q
Mob. No. +91 8291240072

*Please note that this intimation is being submitted without the signature pursuant to Guidelines for submissions in the wake of COVID 19 virus.